• License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe
  • Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company's recent New Dietary Ingredient Notification (NDIN) to market Australian Chestnut Extract in the U.S.
     

WASHINGTON, June 11, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) (the "Company" or "60 Degrees Pharma"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the Company has executed a patent licensing agreement with Florida State University to commence large-scale production techniques to extract and purify castanospermine from the seeds of Castanospermum australe (commonly known as the Australian Chestnut, the Moreton Bay Chestnut, and the Black Bean Tree) for non-prescription uses. Castanospermine is the principal component of Australian Chestnut Extract.

According to recent scientific literature, at low doses, castanospermine modulates carbohydrate metabolism, altering glycogen, glucose levels and other clinical markers. In animal models, high doses have been shown to impact disease outcomes in several therapeutic areas through immunomodulation.

The U.S. Food and Drug Administration (FDA or "the Agency") has issued a Non-Notification Letter to 60 Degrees Pharma providing feedback on the Company's recent filing of a New Dietary Ingredient Notification (NDIN) for Australian Chestnut Extract. 60 Degrees Pharma and the Agency will meet on July 1, 2026, to discuss the feedback, including clarification regarding the minimum required "other safety information" to establish the safety of the proposed use of Australian Chestnut Extract in a dietary supplement. Subsequently, the Company will submit a revised NDIN.